Endologix, Inc. to Announce First Quarter 2017 Financial Results on May 4, 2017
18 April 2017 - 6:01AM
Business Wire
Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of
innovative treatments for aortic disorders, today announced that it
will report financial results for the first quarter of fiscal year
2017 after the market close on Thursday, May 4, 2017. The Company’s
management will host a conference call at 4:30 p.m. ET that same
day to discuss the results.
To participate in the conference call, dial 877-407-9716
(domestic) or 201-493-6779 (international).
This conference call will also be webcast and can be accessed
from the “Investors” section of the Company’s website at
www.endologix.com. The webcast replay of the call will be available
at the same site approximately one hour after the end of the
call.
A recording of the call will also be available from 7:30 p.m. ET
on Thursday, May 4, 2017, until 11:59 p.m. ET on Thursday, May 11,
2017. To hear this recording, dial 844-512-2921 (domestic) or
412-317-6671 (international) and enter the passcode 13660133.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and,
if left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is
approximately 80%, making it a leading cause of death in the
United States. For more information,
visit www.endologix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170417005824/en/
InvestorsEndologix, Inc.Vaseem Mahboob, CFO, 949-595-7200
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2024 to May 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Endologix Inc (NASDAQ): 0 recent articles
More Endologix, Inc. (MM) News Articles